The RETRAIN Trial Phase 2

Inclusion Criteria: 1. Adult over 18 2. Patient with ischaemic stroke diagnosis confirmed by a stroke physician. 3. Within 36 hours of symptom onset. 4. Unable to stand or mobilise without assistance. 5. No intracerebral haemorrhage as ruled out by computerised tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Exclusion Criteria: 1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee. 2. Absence of a transient ischaemic attack (TIA). 3. Clinically apparent deep vein thrombosis at screening 4. Patient is expected to require palliative care within 14 days 5. No response to the geko® device i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting. 6. Contraindications for the use of the geko™ device * Allergy to hydrogel constituents 7. Contraindications to IPC * Severe peripheral vascular disease * Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion) * Severe oedema * Leg deformities making appropriate fitting impossible * Symptomatic congestive cardiac failure of NYHA class IV (symptoms of heart failure at rest, any physical activity causing further discomfort). 8. Single or double leg amputations. 9. Participation in any other clinical trial 10. Patients must not have a current coronavirus (COVID-19) infection